SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

OncoCyte Corp – ‘10-K’ for 12/31/15 – ‘EX-10.22’

On:  Wednesday, 3/30/16, at 4:50pm ET   ·   For:  12/31/15   ·   Accession #:  1140361-16-59543   ·   File #:  1-37648

Previous ‘10-K’:  None   ·   Next:  ‘10-K/A’ on 5/24/16 for 12/31/15   ·   Latest:  ‘10-K’ on 4/16/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/30/16  OncoCyte Corp                     10-K       12/31/15    6:2.6M                                   Broadridge Fin’l So… Inc

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Oncocyte Corporation 10-K 12-31-2015                HTML    654K 
 2: EX-10.21    Material Contract                                   HTML    156K 
 3: EX-10.22    Material Contract                                   HTML     12K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML      6K 
 5: EX-31       Certification -- Sarbanes-Oxley Act - Sect. 302     HTML     17K 
 6: EX-32       Certification -- Sarbanes-Oxley Act - Sect. 906     HTML      9K 


EX-10.22   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 

Exhibit 10.22
 
FIRST AMENDMENT TO LICENSE AGREEMENT
 
This First Amendment (the "First Amendment") is made effective as of January 25, 2016 (the "First Amendment Effective Date"), to amend the License Agreement entered into by and between The Wistar Institute of Anatomy and Biology ("Wistar") and OncoCyte Corporation ("OncoCyte"), dated January 22,2016 (the "License Agreement").
 
PURPOSE OF AMENDMENT
 
The sole purpose of this First Amendment is to correct the numbering found within Section 1.24 of the License Agreement. Section 1.24 shall be deleted in its entirety and replaced with the following:
 
1.24        "Licensed Product(s)" means:
 
(i)         on a country-by-country basis, any product, the making, using, selling, offering for sale, or importing of which product in the country in question would (without the license granted under this Agreement) infringe at least one pending Valid Claim (were it to have issued) or issued Valid Claim of the Licensed Patents in that country;
 
(ii)        on a country-by-country basis, any service, process or method, the performing or providing of which process or method in the country in question would (without the license granted under the Agreement) infringe at least one pending Valid Claim (were it to have issued) or issued Valid Claim of the Licensed Patents in that country; and
 
(iii)       any product or process that is not covered by the foregoing clauses (i) or (ii), but that incorporates or is made, identified, developed, optimized, characterized, selected, derived or determined to have utility, in whole or in part, by the use or modification of (a) any Licensed Patent or any technology or invention covered thereby, (b) any Technical Information or (d) any Licensed Product covered by the foregoing clauses (i) or (ii).
 
This First Amendment shall be binding upon both parties as of the First Amendment Effective Date.
 
All capitalized terms not expressly defined herein shall have the same meanings assigned to them in the License Agreement. Except as expressly amended or modified herein, all other terms and conditions of the License Agreement remain in full force and effect.
 
This First Amendment shall be construed by and enforced in accordance with the laws of the Commonwealth of Pennsylvania without regard to its principles of conflicts of law.
 
IN WITNESS WHEREOF, the parties have caused this First Amendment to be executed by their duly authorized representatives as of the First Amendment Effective Date.
 
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
ONCOCYTE CORPORATION
 
 
By:
/s/ Heather Steinman
By:
/s/ William Annett
Name: Name:
Title:
Vice President for Business Development &
Executive Director, Technology Transfer
Title:
C E O
 
The Wistar Institute
Date:
Date:
January 25, 2016    
 
 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/30/168-K
1/25/16
For Period End:12/31/1510-K/A,  3,  SC 13D
 List all Filings 
Top
Filing Submission 0001140361-16-059543   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 3:52:09.2pm ET